logo-loader
AIM:TRX

Tissue Regenix Group PLC

Receive alerts
Market:
AIM
Market Cap:
£24.62 m
Price
0.35 GBX
Change
6.06%
52 weeks high
4.60
52 weeks low
0.28

Description

The US is the largest healthcare market in the world and where we see the greatest opportunity.

We intend to leverage our platform technologies dCELL® and BioRinse™ to further our market penetration through a hybrid sales model, a combination of direct sales, distribution and OEM agreements.

2018 Performance

Significant OEM agreement signed with Arthrex for the BioRinse™ portfolio in the US market

Extension to the Premier, Inc. GPO Agreement

"Supplier Horizon Award" achievement from GPO, Vizient, Inc.

Uptake by prestigious US establishments such as the Cleveland Clinic

Focus and Goals for 2019

Scale:

Focus on higher volume accounts

SurgiPure® XD US launch

Expand partners for specific fields of use and OEM

New Product Development related to market opportunities

Expand Group Purchasing Organisation coverage

Expand commercial scale

Expand portfolio penetration in existing accounts

BIOSURGERY

Click here for the overview

ORTHOPAEDICS

Click here for the overview

DENTAL

Click here for the overview

CARDIAC

Click here for the overview

Leeds and Texas.

The Board

Kirsten Lund
Chief Financial Officer

Alan Miller
Non Executive-Director

Randeep Singh Grewal
Non Executive-Director

Jonathan Glenn
Non-Executive Director

Shervanthi Homer-Vanniasinkam
Non-Executive Director


 

Telephone
+44 (0)330 430 3052

Email
[email protected]

Fax
+44(0)190438517

Investor or Media Enquiries
Caitlin Pearson
Head of Communications
[email protected]

ADDRESS

UK OFFICE

Unit 1 & 2
Astley Way,
Swillington,
Leeds
LS26 8XT

US OFFICE
1808
Universal City Blvd,
Universal City,
Texas
78148

KEY ADVISORS

Nominated Advisor and Broker
STIFEL NICOLAUS EUROPE LIMITED

150 Cheapside,
London,
EC2V 6ET

Auditors
RSM

Central Square,
29 Wellington St,
Leeds
LS1 4DL

Solicitors
DLA PIPER UK LLP

Princes Exchange,
Princes Square,
Leeds,
LS1 4BY

Registrars
CAPITA

4 Beckenham Rd,
Beckenham,
Kent,
BR3 4TU

Significant shareholders

As at 19 February 2019, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

Name of Shareholder % of Voting Rights
Invesco Limited 28.74
Woodford Investment Management LLP 26.00
Techtran Group Limited 8.79
Baillie Gifford & Co Ltd 6.04
Jupiter Asset Management 5.88
Directors & Related Holdings 4.28
IP2IPO Limited 4.27

Shares not in public hands as at 19 February 2019 – 856,002,530 - 73%

Shares in issue as at 19 February 2019 - 1,171,730,823 ordinary shares of 0.5p each

The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

KEY ADVISORS

Nominated Advisor and Broker
STIFEL NICOLAUS EUROPE LIMITED

150 Cheapside,
London,
EC2V 6ET

Auditors
RSM

Central Square,
29 Wellington St,
Leeds
LS1 4DL

Solicitors
DLA PIPER UK LLP

Princes Exchange,
Princes Square,
Leeds,
LS1 4BY

Registrars
CAPITA

4 Beckenham Rd,
Beckenham,
Kent,
BR3 4TU